Related Experiment Video
Updated: Jun 25, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Metabolic Diseases Drug Discovery World Summit
1Metabolic Disease Research, R4MC, AP10, 100 Abbott Park Road, Abbott Park, IL 60064-6098, USA. gang.liu@abbott.com
Expert Opinion on Emerging Drugs
|December 10, 2003
Summary
Researchers convened at the Metabolic Diseases Drug Discovery World Summit to discuss advancements in treating type II diabetes, metabolic syndrome, and obesity. Key topics included target identification, lead optimization, and clinical trial updates for metabolic disease therapies.
Area of Science:
- Metabolic Diseases
- Drug Discovery and Development
- Pharmaceutical Research
Background:
- The Metabolic Diseases Drug Discovery World Summit convened researchers from the pharmaceutical and biotech industries.
- The summit focused on recent advances in the treatment of type II diabetes, metabolic syndrome, and obesity.
Framework:
- The program encompassed basic physiology relevant to metabolic diseases.
- Therapeutic target identification and validation strategies were discussed.
- Lead compound development and optimization techniques were presented.
Implementation:
- Profiling of drug development candidates was a key area of focus.
- Updates on ongoing clinical trials for metabolic disease treatments were shared.
Implications:
- The symposium highlighted significant developments in the pipeline for metabolic disease therapeutics.
- This meeting facilitated knowledge exchange on cutting-edge approaches to metabolic disease drug discovery.
Related Concept Videos
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...